See all COVID-19 research updates, including updated human-subjects research guidance and participant screening script, here.
Penn State College of Medicine’s Clinical Trials Office enhances, fosters and promotes organized, high-quality clinical research. By promoting clinical research, the Clinical Trials Office helps Penn State Health and Penn State College of Medicine meet the mission goals of excellence in patient care, education, research and community service.
Each year, the College of Medicine approves more than 400 new clinical research studies, with investigators conducting research in 1,500 ongoing studies. Many of these studies utilize the services of the Clinical Trials Office. Since its establishment in the 1990s, the office has grown to offer services such as include protocol and budget feasibility assessment, budget preparation and negotiation, regulatory and IRB submission and oversight, study coordinator services and clinical trial placement.
Jump to topic
This searchable directory provides a quick reference to the many templates, forms, policies and resources described elsewhere on this page.
The clinical research guidebook was developed to provide a one-stop guide for faculty and staff members engaged in clinical research at Penn State College of Medicine/Penn State Health Milton S. Hershey Medical Center.
It has been adapted from the materials created and released by The Clinical Trials Resource Group at the University of California-Davis CTSC.
This information is extracted from CATS IRB for studies that have submitted a modification requesting the use of Studyfinder for recruitment.
The Study Tracking and Analysis for Research (STAR) system is a comprehensive online tool designed to facilitate the submission, approval and management of select clinical research studies within Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine.
STAR is part of Penn State’s Centralized Application Tracking System (CATS) and is integrated with CATS IRB.
Latest Clinical Research News
Protocol and Budget Support
The Clinical Trials Office determines protocol feasibility, analyzes the research budget and may submit regulatory documents.
For clinical research study proposals that do not meet the criteria to be submitted to STAR, a specific process is to be followed during IAF creation in order to provide the appropriate information about the study to CTO and ORA.
Prior to protocol and budget review by the Clinical Trials Office, a Confidentiality Disclosure Agreement (CDA), also known as a Non-Disclosure Agreement (NDA), must be in place.
The Clinical Trials Office provides payer coverage analysis, which is a review of research-related documents to determine the Medicare billing status of both the study and the items/services provided to research subjects as part of a research study.
The coordinator worksheet requires study coordinators to complete only a personnel costs page when submitting a study in STAR.
Study teams should upload the coordinator worksheet to STAR before attending the budget/feasibility meeting. The worksheet can be uploaded using the “Upload Budget Documents” activity on the Budget Workspace (under the Internal Budget section). Once uploaded as COORDINATOR_WORKSHEET, the document will reside in the Budget Workspace under the Documents tab.
Download the Coordinator Worksheet from Box
(Penn State Access ID login required)
This patient care guidance chart is intended as a general guideline for use in determining which items and services should be budgeted as patient care costs on a grant application. In general, patient care costs are those services that are provided in the hospital or clinic setting.
This primarily pertains to federal and federal flow-through projects.
The following additional links provide a breakdown of startup budget considerations and guidance and resources for ongoing financial study management for clinical research.
- Office of Sponsored Programs fringe and F&A rate agreements
- Penn State Policy RA30 (Facilities and Administrative F&A Costs)
- Penn State Policy RA90 Finalization & Closure (formerly RAG 05 and RAG 08)
- Guidelines for financial management of industry-sponsored clinical trials
- Sponsor invoice template (available in Box; Penn State Access ID login required)
Effective July 1, 2020, Penn State College of Medicine and Penn State Health have transitioned away from gift cards and checks for reimbursement/payment for clinical research participants. Greenphire ClinCards will replace all previous forms of reimbursement/payment.
For details, contact the Controller’s Office (part of the College of Medicine Finance and Business team.
A set of Standard Operating Procedures for Clinical Research describes the preparation and maintenance that the research team follows to ensure compliance with all FDA regulations and guidelines, and the policies and procedures of the College of Medicine and Penn State for all clinical trials conducted at Penn State.
These procedures are currently under revision and will be distributed when that process is complete. With specific questions in the interim, contact the Clinical Trials Office.
For proposals that do not meet the criteria to be submitted to STAR, investigators must submit an Internal Approval Form, or IAF, to the Office of Research Affairs. (This is generally used for industry-sponsored clinical trials.)
The College of Medicine Business and Finance office also has a set of guidelines for the financial management of industry-sponsored clinical trials.
Device Trial Information
Note: The Medicare Administrative Contractor (MAC) for Penn State Health/Penn State College of Medicine is Novitas Solutions Inc. As of July 1, 2013, the jurisdiction is designated as JL instead of J12. Currently, Novitas is requiring faxes (see template in Box; Penn State Access ID login required) rather than mail communications.
The Centers for Medicare & Medicaid Services (CMS) have established regulations for coverage of device trials. These rules are found in the Code of Federal Regulations 42CFR 405.201 – 405.215 and 411.215 and 411.406. The study qualifies for Medicare coverage if the device trial meets the criteria in the regulations. In turn, this means routine costs during the qualifying device trial are covered. Even when a device is provided without charge, the MAC must still approve the study for routine costs to be billable.
- For IDEs approved by the FDA on or after Jan. 1, 2015, it is the sponsor’s responsibility to submit to national CMS for “Approval” – not the individual research site providers. Novitas requests certain information be sent to them before institutional claims are submitted. This “Notification” will allow Novitas to add information to their claims payment system to ensure proper processing of claims occurs.
- Penn State Health will fax the “Notification” (see template in Box; Penn State Access ID login required) to Novitas Solutions Inc., including the following:
- CMS Approval Letter including the six-digit IDE Study and eight-digit National Clinical Trial (NCT) numbers
- Name(s) of hospital/facility and their Provider Transaction Access Number(s) (PTAN)
More information can be found on the Novitas Solutions website.
Investigational Device Exemption (IDE)
The FDA recognizes three regulatory classes of medical devices. For purposes of assisting CMS in determining Medicare coverage, the FDA will place all approved IDEs in one of two categories: Category A or Category B.
Investigational Device Categories: Medicare Coverage Principles
For IDEs approved by the FDA on or after Jan. 1, 2015, it will be the sponsor’s responsibility to submit to national CMS and provide Penn State Health with documentation. Penn State Health/Penn State College of Medicine will contact the Medicare Administrative Contractor via fax and receive and receive a confirmation acknowledgement in return.
Category A Device – Experimental
- These consist of novel, first-of-a-kind technologies. They are innovative FDA Class III devices for which the absolute risk of the device type has not been established and initial questions of safety and effectiveness have not been resolved. The FDA is unsure whether these device types can be safe and effective.
- Medicare covers the routine costs of clinical trials involving IDE Category A devices effective for routine costs incurred on or after Jan. 1, 2005.
- This extension of coverage only refers to the routine services performed for such a trial. The Category A device itself remains non-covered.
- See details on the Novitas website under Clinical Trials and Devices.
Category B Device – Non-Experimental/Investigational
- These devices are the newer generations of proven technologies that may be in FDA Class I, II or III. Initial questions of safety and effectiveness of these devices have been resolved, and the incremental risk of this device, generally an update to an existing device, is the primary risk in question.
- Medicare covers the routine costs of clinical trials involving IDE Category B devices effective for routine costs incurred on or after Jan. 1, 2005.
- Medicare covers Category B devices if they are considered reasonable and necessary, and if all other applicable Medicare coverage requirements are met.
- This policy does not infer that all devices classified in Category B will be covered under Medicare.
Coverage with Evidence Development (CED)
CMS provides for a coverage mechanism, referred to as coverage with evidence development (CED), in order to extend coverage for selected medical procedures, contingent upon the collection of additional data. In general, CED allows for coverage of FDA approved medical technologies and services when improvements in health outcomes have not been conclusively demonstrated. There are two types of CED:
- Coverage with appropriateness determination (CAD): The item or service is covered only when specific data are submitted in addition to claims data to demonstrate that the item or service was provided as specified in the NCD (database/registry).
- Coverage with study participation (CSP): The item or service is covered only after a formal National Coverage Determination request has been initiated and it is provided within a setting in which there is a pre-specified process for gathering additional data, and in which that process provides additional protections and safety measures for beneficiaries, such as those present in certain clinical trials (clinical research studies – expect to see an FDA approval letter with an associated IDE number). Sponsor is not required to show additional approval from CMS because it is already approved under the CED.
Humanitarian Device Exemption (HDE) and Humanitarian Use Device (HUD)
- A humanitarian use device (HUD) is intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect or manifest in less than 4,000 individuals in the United States per year.
- An approved HDE authorizes marketing of the HUD. However, the HUD may only be used after IRB approval has been obtained for the use of the device for the FDA-approved indication.
- The HUD may only be used in facilities that have an IRB and after the IRB has approved the use of the device to treat or diagnose the specific disease.
- Medicare covers HDEs if they are considered reasonable and necessary, and if all other applicable Medicare coverage requirements are fulfilled.
- No prior approval will be provided for these devices even if the patient is a participant in a clinical trial. MAC submission is no longer required. However, appropriate documentation, if requested, supporting the medical necessity of the procedure/device for the beneficiary must be made available upon request.
Working with the Electronic Medical Record (EMR)
Penn State Health Milton S. Hershey Medical Center uses the Cerner Millenium system/PowerChart as its EMR. The Penn State Health CareConnect project, which launched in 2018, allowed for integration of the EMR with the patient billing system.
A full set of CareConnect help resources are available on Cerner Wiki (Cerner login required). Specific resources for clinical trials are highlighted here.
CareConnect applications are accessed by clicking the CareConnect desktop icon on any workstation at Hershey Medical Center.
Special instructions have been developed for research external reviewers accessing patient records in the Cerner Millenium PowerChart system.
In PowerChart, clinical trials information is documented and viewed in several places.
Information on how to view and modify clinical trials information, including adding an interdisciplinary narrative note and finding the clinical trials flag on the Alerts tab, and is available on Cerner Wiki.
See walkthrough of PowerChart documentation for clinical trials
(Cerner login required)
In PowerChart, eMessage Pools allow for a notification to be sent to a group of users who are part of a message pool. This is especially helpful when a research participant who is identified by the Alerts Tab has an OOS created for any ER visit, inpatient hospitalization or observation stay.
Admission notifications can only be sent to a message pool, not individual email accounts. Message pools can also be used for clinical staff to send messages to a research team.
Information on how to set up and use eMessage Pools can be found via the Cerner Wiki, including:
- Basic guide to direct messaging
- How to add contacts to the personal address book
- How to add or remove individuals from Pools
See all eMessaging guides on Cerner Wiki
(Cerner login required)
Other information on eMessaging can be found in the CareConnect Infonet section (internal access only; Penn State Health ePass login required).
Because of increasing concerns about cybersecurity and HIPAA, Penn State Health provides a Cerner tool that allows the organization to limit the visibility of external monitors/auditors coming to the site to review EMR data for participants enrolled in clinical trials.
In the Relationship Management Tool, study teams can create a patient list and assign that list to specific monitor(s); then, those monitors will only be able to see patients for that particular study and not have access to the entire EMR.
Regulatory Binder Instructions
This guide is adapted from the Partners Human Research Quality Improvement Program and Enterprise Research Infrastructure and Services, in affiliation with Harvard Catalyst.
A regulatory binder assists sites in achieving and maintaining regulatory compliance and ensuring the highest standards of human subject research. The binder also provides:
- Guidance for organization and record-keeping
- Assistance with proper study documentation and successful study management
- Access to additional information and online resources, such as IRB/HSPO policies, guidelines, forms and federal regulations
A set of regulatory binder dividers is available to assist investigator-initiated study teams who are creating their own binders.
Each binder divider outlines the regulatory requirements, institutional policies and GCP guidelines for organization and record-keeping that pertain to that section. The bottom of each binder tab includes QI tips, links to QI tools and references for applicable requirements.
General Guidance for Using a Regulatory Binder
- The regulatory binder should be established at the beginning of the study, prior to enrollment.
- Keep the regulatory binder current and up-to-date.
- Each team should identify the individual(s) responsible for maintaining the binder and ensure that this person is on file with the IRB as contact person to ensure that all IRB correspondence and documents are received/filed in a timely manner.
- Store binder in a safe and secure location, but accessible to study staff at all times. If sections of the binder are stored in a separate location (centrally filed) or maintained electronically, write a signed and dated note-to-file indicating the location and who maintains them. File the note behind the tab to which it applies.
- Subject-specific documentation and information (e.g., signed consent forms, test results and completed case report forms) should be maintained separately within the subject-specific binder/file.
- Customize the binder to meet the needs of the protocol. The sample tabs are a template. Teams should include only sections pertinent to their protocol, omitting unused sections and adding sections as needed. (See “Applicable sections” below for more information.) Teams unsure of what sections to include/exclude should contact Research Quality Assurance to clarify.
Depending on the nature of the research, some tabs may not be required. Use the list below to ensure that the applicable sections are maintained.
- Staff CVs
- Staff licensures
- IRB documents
- Consent forms
- Data collection/CRFs
- Lab documents
- Drug/device accountability
- Financial disclosure
Penn State’s electronic regulatory (eReg) binder is a REDCap project adapted by the Department of Public Health Sciences Data Management Unit from the eReg binder developed by the Partners Human Research Quality Improvement Program and Enterprise Research Infrastructure and Services in affiliation with Harvard Catalyst.
The purpose of the eReg binder is to assist investigators with the electronic storage and organization of the regulatory documentation used in human-subject research for tracking and reviewing the implementation of clinical research protocols approved by the Institutional Review Board and Research Quality Assurance at Penn State College of Medicine.
The binder is a flexible tool and can be utilized by single and multi-site studies and customized to meet the needs of a specific research protocol.
The eReg binder is divided into multiple sections, each of which contains templates designed to help investigators achieve and maintain regulatory compliance and adhere to federal, institutional and Good Clinical Practice guidelines for research involving human subjects.
The eReg binder templates are for investigator-initiated trial use. Sponsored studies should follow sponsor guidelines for storage of regulatory materials.
For questions related to eReg binders, email eReg@phs.psu.edu.
The following documents may assist with eReg binder creation.
Commonly Used Research Acronyms
Following a Pennsylvania Supreme Court decision regarding informed consent and the effect on the research consent process, it was determined that the proper course of action would be the development of an “Affirmation of Consent Required by Pennsylvania Law.”
Communication to Faculty
This communication was provided to faculty from Neal Thomas, MD, MSc, Associate Dean for Clinical Research:
In a follow-up to the email you received in August, we have had further discussions about how best to operationalize the divergent requirements of the federal and state laws regarding informed consent and the effect on our research consent process. After discussion with other research institutions in Pennsylvania, we have determined that the proper course of action would be the development of an “Affirmation of Consent Required by Pennsylvania Law.”
This Affirmation should be used when “administering an experimental medication, using an experimental device or using an approved medication or device in an experimental manner” to meet the requirements of Pennsylvania’s MCARE Act. The Affirmation should be signed by the physician investigator overseeing that particular patient enrollment in the trial, attached to the IRB-approved informed consent for research document and uploaded into the electronic medical record. Physicians performing other procedures in the course of a research protocol requiring informed consent under the MCARE Act should continue to utilize approved forms, such as MR 21.
The Affirmation is being implemented to address a clinical treatment requirement, not a research requirement. As such, its use will not be subject to review of the Human Subjects Protection Office, which is governed by federal law.
Use is only required when patients who are being treated at a Penn State Health facility are given an experimental medication or device, and will serve to confirm that the physician investigator overseeing the administration of the experimental medication or device had a personal discussion of the intervention and allowed adequate time for questions from the research subject or legally authorized representative.
Further questions related to the interpretation of the MCARE Act can be addressed by Nicole Lehman in the Office of General Counsel. Questions related to the operationalization of this Affirmation can be addressed by Dr. Neal Thomas, Associate Dean for Clinical Research.
Form MR1960: Affirmation of Consent for Research
To access the MR1960 form:
- Log in to the Digital Storefront of the Print Shop.
- In the Search Product field at the top of that page, enter MR 1960 (being sure to include the space).
- Click on the form that opens in the window.
- The form can be ordered from the Print Shop; alternately, investigators may click on the “Preview” link and download the form to print individually. Note: It is recommended that investigators who wish to print the form themselves visit the Print Shop Digital Storefront each time and download the file again in order to ensure they are using the most up-to-date version.
The information in this form may be provided to clinical research sponsors and contract research organizations (CRO) should there be questions about the process.
A Certificate of Confidentiality is a document issued by the FDA or NIH that:
- protects researchers and institutions from outside authorities collecting personally identifiable and sensitive information and
- permits researchers and institutions to refuse to disclose identifying information on research subjects in any civil, criminal, administrative, legislative or other proceeding (e.g., under subpoena, court order).
For questions about Certificates of Confidentiality, contact IRB/HSPO.
When the sponsor requires completion of a sponsor-provided checklist for validation of any Penn State Health/Penn State College of Medicine IT systems and resources, initiate the Request IS Service form and attach the checklist for completion.
Complete the Request IS Service form here (Penn State Health ePass login required)
According to CDERs Division of Scientific Investigations, “records must be stored under conditions that will preserve their integrity, and that sites be able to retrieve and provide prompt access to such records if the FDA requests such records as part of an inspection”.
The Penn State Inactive Records Center was developed to provide such storage at low rates.
For short-term storage of records on-site in Hershey, contact the College of Medicine Clinical Trials Office at email@example.com.
Penn State College of Medicine’s digital systems have not had their compliance validated for electronic signature. When requested to provide assurance, investigators should use this statement:
“All persons granted access to the electronic medical record (eMR) (Cerner Millennium – Connected) undergo training in the operation and proper use of the system and are assigned specific access rights to system functions. Persons with signatory authority in the eMR have verified that their electronic signature is equivalent to their written signature (copy provided upon request). All employees of Penn State Health Milton S. Hershey Medical Center (PSHMSHMC) and College of Medicine have been informed of and have agreed to abide by the standards of the University and PSHMSHMC with respect to privacy, confidentiality, security and dissemination of all electronic records and communications. At the present time we cannot assure that all of our systems are fully compliant with all provisions of 21CFR11.”
Study teams may be required to provide a certified copy of the electronic medical record in order to meet the requirements for the provision of source documents as per the Code of Federal Regulations and ICH Good Clinical Practice guidelines for patients enrolled in a clinical research study.
If this is necessary, a member of the study team should complete the form below and fax to the dedicated number listed on it.
Download a Word template of the request form from Box; Penn State Access ID login required.
The Investigational Drug Service (IDS) at Penn State Health Milton S. Hershey Medical Center is charged with the control and management of investigational (research) drugs used in clinical (human) research trials throughout the institution.
See information about the Investigational Drug Service Pharmacy on the Pharmacy section of the Infonet (internal access only; Penn State Health ePass login required). Study teams may also print the Investigational Drug Service Information Sheet from Box.
See all Investigational Drug Services policies in the Policy Portal (Penn State Health ePass login required).
For copies of current CV and licensure for Investigational Drug Services staff, contact the Clinical Trials Office.
Monitors must be granted Penn State Health ePass and CareConnect access.
Note that due to COVID-19, on-site monitoring is not possible and all monitoring visits are being conducted remotely. All monitors with existing accounts have remote access, and the instructions here have been updated to note how to request it for new monitors.
All monitors must follow these instructions for setting up Duo two-factor authentication and logging on to the remote access portal before attempting to access the CareConnect software.
Requesting Access for Monitors/Sponsors
The Electronic IS Account Request Form (in ServiceNow; Penn State Health ePass login required) must be completed by the internal sponsor prior to account authorization being given. It may take two to three weeks for the access request to be processed, so study teams should plan accordingly.
Note: Before beginning this process, the on-site study team must gather certain information from the external monitor using the IS External Personal Information Form, available on the IS Infonet section (internal access only; Penn State Health ePass login required).
A guide to the specific use of the electronic account request form for monitor/sponsor access appears here; a general quick-reference guide and job aid for using the electronic account request form are available on the IS Infonet section (internal access only; Penn State Health ePass login required).
Request type: Choose “New/Change – PSH Staff or Non-Employee (contractor/vendor/student/faculty).”
Does the applicant have a current PSH/COM login (ePass)? Choose “No.”
Applicant personal information and address: Enter the contractor’s information.
- For Employee Type, select “External Contractor/Vendor.”
- For Business Entity, select applicable organizational site.
- For Title/Job Description, type “Research Monitor/Auditor.”
- For Hiring Department, list the department requesting access.
- For Work Location, list the name of department requesting access and location where monitor/sponsor representative will be working from (e.g. Clinical Trials Office, SSB Room 200L, or “remote”).
- Provide questions and responses to two security questions.
PSU ID: Select “No.”
- Check the box next to “CareConnect.”
- For Add/Change or Remove, select “Add/Change.”
- For Is This a Secondary CareConnect account, select “No.”
- For Position, select “Research External Reviewer.”
- Check the box next to “Remote Access.”
- For Remote Access: Add/Change or Remove, select “Add.”
- For Remote Type, select “AnyConnect VPN.”
- For Business Justification for Remote Access, write “Remote access utilizing Relationship Management Tool for clinical research monitors.”
Were you able to find all the items you needed to request access for? Choose “Yes.”
When finished, click “Submit” at right to submit the account request.
The monitor/sponsor must complete HIPAA, Privacy and Information Protection training. Changes to this system are forthcoming; in the meantime, study teams should provide this HIPAA Substitute Training for Monitors document (available in Box) to their monitors/sponsors for completion.
Currently, account authorization will be audited approximately every three months. The person listed as the Manager/Supervisor/Chair on the form will receive a call from IT Account Management, who will verify that the individual still needs access, the anticipated date of completion, etc. Account Management will also be auditing records to be sure the individual accessed only the records they were supposed to.
On-Site Monitoring Space
There is monitoring space available in the Clinical Research Services area at the Support Services Building.
Email CTO@pennstatehealth.psu.edu to inquire about reserving space. It is never a good idea to have monitors working in study team workspaces or in open spaces throughout the institution.
On-Site Monitoring Guidelines
A document describing on-site monitoring guidelines is available to provide to monitors. Download the document from Box (Penn State Access ID login required).
The following documents are the most current on file and may be used in regulatory site files as required by the sponsor.
For copies of the current CV and license for the Clinical Laboratory director, Special Hematology Laboratory director and Investigational Drug Services staff, email CTO@pennstatehealth.psu.edu.
The success of a clinical research study depends on skilled coordination and collaboration among multiple disciplines.
Competent and well-trained clinical research personnel fulfill a central role in this process. To ensure that the research program at Penn State Health Milton S. Hershey Medical Center is of the highest quality, a competency-based orientation guide for clinical research personnel has been developed that is geared to novice and recently employed individuals at the medical center.
Based on the diverse locations and reporting responsibilities of research personnel at Penn State Health Milton S. Hershey Medical Center, this orientation material attempts to provide quality and consistency to orientation by focusing on a basic core body of knowledge.
New personnel complete this self-paced training under the guidance of an adviser. The training includes 13 essential competency areas and specific criteria necessary to achieve each competency.
The references provided in the competencies refer to both industry-sponsored and investigator-initiated research. The goal is to aid research personnel in understanding the regulatory requirements, as well as maintaining and promoting high ethical standards for the conduct of research.
Penn State College of Medicine and Penn State Health departments and programs are encouraged to adapt this material as necessary to meet specific programmatic needs, being sure to cite Maine Medical Center. Information from this manual may not be distributed for profit.
- Core Competency 1: Good Clinical Practice Training
- Core Competency 2: Protocol Development/Evaluation
- Core Competency 3: Financial Management
- Core Competency 4: Clinical Trial Agreement/Grant Proposal
- Core Competency 5: Planning for Protocol Implementation
- Core Competency 6: HSPO/IRB Communication
- Core Competency 7: Study Start-up
- Core Competency 8: Informed Consent Process
- Core Competency 9: Ongoing Conduct of Study
- Core Competency 10: Test Article Accountability
- Core Competency 11: Subject Safety/Adverse Events
- Core Competency 12: Document and Data Management
- Core Competency 13: Study Close-out
Competencies are currently under revision and will be posted when completed.
The shipment of dangerous goods, including biological agents and materials, as well as dry ice, is heavily regulated by the federal government and the shipping industry, in particular the Department of Transportation and the International Air Transport Authority.
Strict requirements for packaging, labeling and completion of shipping documentation apply to many such materials shipped from Penn State Health/Penn State College of Medicine. As such, appropriate training in these aspects of dangerous goods shipping is required for any individual who offers these materials for shipment by ground or air transporters.
The training certification is good for two years if shipping by air, or three years for those who only ship by ground.
Complete mandatory Biological Materials and Dry Ice Shipping Training in COMPASS (Penn State Health ePass login required)
With questions on this training, call the Department of Safety at 717-531-7297.
Creation of forms and worksheets for research studies can be a time-consuming and costly activity. These forms and logs are provided for research personnel for use for investigator-initiated studies, or for industry-sponsored studies in which they are not provided by the sponsor.
These study management tools may be revised to fit the needs of study teams, keeping in mind that the goal is to maintain the integrity of the document to meet requirements by any auditing agencies and compliance to College of Medicine standards.
Creation of forms and worksheets for research studies can be a time-consuming and costly activity. These forms and logs are provided for research personnel for use for investigator-initiated studies, or for industry-sponsored studies in which they are not provided by the sponsor.
These subject management tools may be revised to fit the needs of study teams, keeping in mind that the goal is to maintain the integrity of the document to meet requirements by any auditing agencies and compliance to College of Medicine standards.
To become a vendor to Penn State Health, the vendor representative(s) must be registered with:
- Symplr (Penn State Health Milton S. Hershey Medical Center)
- Reptrax (Penn State Health St. Joseph Medical Center)
All vendors are required to abide by all policies and procedures that are uploaded to each of the credentialing platforms.
For details, see Policy A-65 HAM – Vendor Representative Visitation and Solicitation to Clinical and Non-Clinical Work Areas (Penn State Health ePass login required).
Study teams should not schedule meetings or introduce new products/services prior to the vendor being credentialed.
- Center for Medical Innovation
- Clinical and Translational Science Institute
- College of Medicine Business and Finance
- Institutional Review Board/Human Subjects Protection Office
- New Faculty Orientation – Researcher Requirements
- Office of Research Affairs
- Research Concierge/Research Development
- Research Quality Assurance